This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% year over year, according to the newly published IMV 2024 PET Market Summary Report. In 2023, the average number of PETscans per fixed PET site (versus mobile PET) increased 6.7%
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PETscans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
The Medical Imaging and Technology Alliance (MITA) has raised concerns ove. Read more on AuntMinnie.com Related Reading: ACR urges full coverage for amyloid PETscans CMS proposal covers PETscans for Alzheimer’s disease MITA praises FDA for Leqembi approval FIND Act reintroduced in U.S.
Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PETimaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia. of patients, noted lead author Ke-Liang Chen, MD, a neurologist at Fudan University. “In
The following is the list of candidates for the 2024 edition of the Minnies, AuntMinnie.com 's campaign to recognize the best and brightest in medical imaging. Image from Martin W. tesla brain MRI scans. Image from Denis Le Bihan, PhD, of the NeuroSpin research facility, et al. AI detects cancer on breast MRI.
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PETscans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
The promise of imaging One challenge is that advances in Alzheimer’s care can only help people if they are reaching the right patients at the right time in their patient journey. Reimbursement barriers Unfortunately, until recently, there were significant barriers to receiving amyloid PETimaging in some regions.
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Lancet Oncology 2023; 24(3): e133-e143.
30, 2025 Earlier this month, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimers Association released updated appropriate use criteria (AUC) for amyloid and tau PETimaging in patients with mild cognitive impairment, Alzheimers disease and other dementias. tim.hodson Thu, 01/30/2025 - 10:20 Jan.30,
Molecular imaging enables doctors and clinicians to see inside the body with a non-invasive process, helping to diagnose and treat diseases such as cancer, cardiovascular disease , and neurological diseases. It can allow early and precise diagnosis.
Radiopharmaceuticals in diagnostics provide critical insights into disease processes, improving accuracy, patient care, and treatment outcomes significantly. The post The Transformative Power of Radiopharmaceuticals in Diagnostics appeared first on Open MedScience.
PETscans are crucial for detecting metabolic activity, providing valuable insights into cancer, neurological disorders, and cardiovascular diseases. The post How to Read a PETScan: A Basic Understanding appeared first on Open MedScience.
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PETradiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PETimaging currently under review by the U.S.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PETradiopharmaceuticals , today announced U.S. Results demonstrated high detection rates (% positive PETscans) even at low PSA levels.
The first new feature,Centiloid scoring, standardizes the quantification of brain-amyloid plaque in PETscans across three commercially available beta-amyloid PETradiopharmaceuticals used to diagnose Alzheimer’s disease.
Positron Emission Tomography Imaging has advanced with cutting-edge technologies, enhancing diagnostic accuracy and expanding clinical applications dramatically. The post Breakthroughs in Positron Emission Tomography Imaging appeared first on Open MedScience.
It's only been a few years since a dedicated track in nuclear medicine and molecular imaging was established at the meeting, and the practice already dominates it. All studies in the sole slated session on novel radiopharmaceuticals this year are on FAPI-PET tracers. Below is just a sample of the content on offer. 9:10 a.m. |
8, 2025 The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimers Association have released updated appropriate use criteria (AUC) for amyloid and tau PETimaging in patients with mild cognitive impairment, Alzheimers disease and other dementias. tim.hodson Tue, 01/14/2025 - 16:48 Jan.8,
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content